end of compounded semaglutide ๐จ FDA Moves to Permanently Shut Down GLP-1s The FDA is taking steps to eliminate large-scale compounding GLP-1 medications like and tirzepatide, signaling a major shift in how these FDA Warns Against Compounded Semaglutide
Description
Active cardiovascular disease, recent heart attack, or unstable angina

Emerging role of GLP1 agonists in obesity: a comprehensive review of randomised controlled trials

Reductions in A1c levels were similar in any duration of diabetes in DUAL-1 and 2

With key advantages like appetite control and better nutrient absorption, Tirzepatide with B12 has gained significant attention
